Sorrento (SRNE) Says Anti-CEA CAR-T Cell Therapy for Liver Metastases Demonstrates Therapeutic Activity in Stage … – StreetInsider.com
|
Sorrento (SRNE) Says Anti-CEA CAR–T Cell Therapy for Liver Metastases Demonstrates Therapeutic Activity in Stage …
StreetInsider.com Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”), cellular therapy focused subsidiary, TNK Therapeutics, Inc. (“TNK”), and Surefire Medical, Inc., announced today initial results from the Hepatic ImmunoTherapy for Metastases-Surefire, or HITM … |
